Plus Therapeutics (PSTV) Stock Price, News & Analysis

Company Overview

Plus Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of proprietary targeted radiotherapies for the treatment of cancer. Headquartered in Austin, Texas, the company leverages its Radiopharma Development Platform to design and manufacture precision radiation agents that selectively deliver radioactive isotopes directly to tumor sites. By harnessing both beta and alpha emitting isotopes, Plus Therapeutics seeks to address a range of solid tumors and hematological malignancies with the potential for improved safety and efficacy profiles compared to conventional treatments.

The company’s lead product candidate, radioprava™ (90Y silicate microspheres), is designed for selective internal radiation therapy of primary liver cancer (hepatocellular carcinoma) and liver metastases. Radioprava is currently being evaluated in multiple clinical trials, and Plus Therapeutics has initiated patient enrollment at centers across North America and Europe. In addition, the proprietary OctreoPharm® platform utilizes 177Lu-labeled somatostatin analogues to target neuroendocrine tumors, while Radspherin® (212Pb) is being explored for the treatment of peritoneal cancers through the delivery of alpha particle therapy directly into the peritoneal cavity.

Founded in 2014, Plus Therapeutics has built a multidisciplinary team with expertise in radiochemistry, oncology, medical physics, and regulatory affairs. The company’s manufacturing operations include a Good Manufacturing Practice (GMP) facility that enables on-site isotope production and radiopharmaceutical formulation. Strategic partnerships with leading academic institutions and contract development organizations support the execution of clinical studies and the advancement of investigational radiotherapies.

Under the leadership of President and Chief Executive Officer Oliver P. Scherzer and Chief Financial Officer Todd A. Vasiloff, Plus Therapeutics is committed to expanding its pipeline through internal discovery and potential collaborations. With a global clinical footprint and a robust intellectual property estate, the company aims to bring novel targeted radiation therapies to patients with limited treatment options and to establish new standards in the management of solid tumors and disseminated cancers.

Key Stats

• Today's Range: $0.33 to $0.36
• 50-Day Range: $0.18 to $0.70
• 52-Week Range: $0.16 to $2.31
• Volume: 6.49 million shs
• Average Volume: 10.60 million shs
• Market Capitalization: $18.34 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $10.83
• Consensus Rating: Moderate Buy

Plus Therapeutics Stock Analysis - MarketRank™

Plus Therapeutics scored higher than 32% of companies evaluated by MarketBeat, and ranked 758th out of 944 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.3 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Plus Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 2 buy ratings, 2 hold ratings, and no sell ratings.

Amount of Analyst Coverage

Plus Therapeutics has only been the subject of 4 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Plus Therapeutics are expected to grow in the coming year, from ($2.30) to ($1.60) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Plus Therapeutics is -0.12, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Plus Therapeutics is -0.12, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

11.70% of the float of Plus Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Plus Therapeutics has a short interest ratio ("days to cover") of 0.2, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Plus Therapeutics has recently increased by 390.60%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Plus Therapeutics does not currently pay a dividend.

Dividend Growth

Plus Therapeutics does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

11.70% of the float of Plus Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Plus Therapeutics has a short interest ratio ("days to cover") of 0.2, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Plus Therapeutics has recently increased by 390.60%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 2.2 / 5
• News Sentiment: 0.00

News Sentiment

Plus Therapeutics has a news sentiment score of 0.00. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.99 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 4 news articles for Plus Therapeutics this week, compared to 2 articles on an average week.

Search Interest

44 people have searched for PSTV on MarketBeat in the last 30 days. This is an increase of 193% compared to the previous 30 days.

MarketBeat Follows

6 people have added Plus Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 50% compared to the previous 30 days.

Company Ownership

• Score: 0.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Plus Therapeutics insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 3.76% of the stock of Plus Therapeutics is held by insiders.

Percentage Held by Institutions

Only 3.28% of the stock of Plus Therapeutics is held by institutions.

PSTV Stock Analysis - Frequently Asked Questions

How have PSTV shares performed this year?

Plus Therapeutics' stock was trading at $1.15 at the beginning of 2025. Since then, PSTV shares have decreased by 68.7% and is now trading at $0.3597.

How were Plus Therapeutics' earnings last quarter?

Plus Therapeutics, Inc. (NASDAQ:PSTV) released its quarterly earnings results on Friday, May, 30th. The company reported ($0.56) EPS for the quarter, missing analysts' consensus estimates of ($0.17) by $0.39. The company had revenue of $1.06 million for the quarter, compared to the consensus estimate of $1.11 million.

When did Plus Therapeutics' stock split?

Shares of Plus Therapeutics reverse split before market open on Monday, May 1st 2023.The 1-15 reverse split was announced on Monday, May 1st 2023. The number of shares owned by shareholders was adjusted after the closing bell on Monday, May 1st 2023. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split.

How do I buy shares of Plus Therapeutics?

Shares of PSTV stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Plus Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Plus Therapeutics investors own include Meta Platforms (META), CymaBay Therapeutics (CBAY), Advanced Micro Devices (AMD), NVIDIA (NVDA), Arista Networks (ANET), Broadcom (AVGO) and Adobe (ADBE).

Company Calendar

• Last Earnings: 5/30/2025
• Today: 7/13/2025
• Next Earnings (Estimated): 8/13/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - DRUGS
• Sub-Industry: Medical Equipment
• Current Symbol: NASDAQ:PSTV
• CIK: 1095981
• Web: www.plustherapeutics.com
• Phone: 737-255-7194
• Fax: 858-450-4335
• Employees: 20
• Year Founded: 1996

Price Target and Rating

• Average Price Target for Plus Therapeutics: $10.83
• High Price Target: $20.50
• Low Price Target: $3.00
• Potential Upside/Downside: +2,911.8%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.50
• Research Coverage: 4 Analysts

Profitability

• EPS (Trailing Twelve Months): ($2.94)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$12.98 million
• Net Margins: -520.90%
• Pretax Margin: -520.90%
• Return on Equity: N/A
• Return on Assets: -202.73%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 1.03
• Quick Ratio: 1.03

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($1.52) per share
• Price / Book: -0.24

Miscellaneous

• Outstanding Shares: 50,998,000
• Free Float: 49,080,000
• Market Cap: $18.34 million
• Optionable: Not Optionable
• Beta: 0.69